Five year trends in dyslipidaemia prevalence and management in Switzerland: the CoLaus study

Nutrition, Metabolism, and Cardiovascular Diseases : NMCD
Panagiotis AntiochosPeter Vollenweider

Abstract

Data from prospective cohorts describing dyslipidaemia prevalence and treatment trends are lacking. Using data from the prospective CoLaus study, we aimed to examine changes in serum lipid levels, dyslipidaemia prevalence and management in a population-based sample of Swiss adults. Cardiovascular risk was assessed using PROCAM. Dyslipidaemia and low-density lipoprotein cholesterol (LDL-C) target levels were defined according to the Swiss Group for Lipids and Atherosclerosis. Complete baseline and follow up (FU) data were available for n = 4863 subjects during mean FU time of 5.6 years. Overall, 32.1% of participants were dyslipidaemic at baseline vs 46.3% at FU (p < 0.001). During this time, lipid lowering medication (LLM) rates among dyslipidaemic subjects increased from 34.0% to 39.2% (p < 0.001). In secondary prevention, LLM rates were 42.7% at baseline and 53.2% at FU (p = 0.004). In multivariate analysis, LLM use among dyslipidaemic subjects, between baseline and FU, was positively associated with personal history of CVD, older age, hypertension, higher BMI and diabetes, while negatively associated with higher educational level. Among treated subjects, LDL-C target achievement was positively associated with diabetes and ne...Continue Reading

References

Dec 17, 2005·The American Journal of Medicine·Leif R Erhardt
Aug 25, 2009·Atherosclerosis·Mingfang LiBernard M Y Cheung
Feb 20, 2010·European Journal of Cardiovascular Prevention and Rehabilitation : Official Journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology·Andres JaussiRoger Darioli
Aug 13, 2010·The Annals of Pharmacotherapy·Devin M MannIan Kronish
Feb 8, 2011·Lancet·Farshad FarzadfarUNKNOWN Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Cholesterol)
Aug 3, 2013·European Heart Journal·Rajiv ChowdhuryOscar H Franco

❮ Previous
Next ❯

Citations

Sep 21, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Assem ZhakupovaThorsten Hornemann
Jun 22, 2017·European Journal of Clinical Pharmacology·Nazanin AbolhassaniGérard Waeber
Mar 27, 2021·Scientific Reports·Julien CastioniPedro Marques-Vidal
Sep 15, 2021·Current Medical Research and Opinion·Vivencio BarriosAnastassia Anastassopoulou

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Cardiovascular Disorder in Diabetes

Diabetes is associated with an increased risk of cardiovascular disorders and heart failure. Discover the latest research here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.